ES2679798T3 - Método para proporcionar linfocitos T específicos de tumor - Google Patents

Método para proporcionar linfocitos T específicos de tumor Download PDF

Info

Publication number
ES2679798T3
ES2679798T3 ES16753630.9T ES16753630T ES2679798T3 ES 2679798 T3 ES2679798 T3 ES 2679798T3 ES 16753630 T ES16753630 T ES 16753630T ES 2679798 T3 ES2679798 T3 ES 2679798T3
Authority
ES
Spain
Prior art keywords
tumor
nucleic acid
specific
clones
lymphocyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16753630.9T
Other languages
English (en)
Spanish (es)
Inventor
Rudolf Hammer
Steffen Hennig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HS DIAGNOMICS GmbH
Original Assignee
HS DIAGNOMICS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HS DIAGNOMICS GmbH filed Critical HS DIAGNOMICS GmbH
Application granted granted Critical
Publication of ES2679798T3 publication Critical patent/ES2679798T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
ES16753630.9T 2015-08-10 2016-08-10 Método para proporcionar linfocitos T específicos de tumor Active ES2679798T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15180383 2015-08-10
EP15180383 2015-08-10
EP15202419 2015-12-23
EP15202419 2015-12-23
PCT/EP2016/069041 WO2017025564A1 (en) 2015-08-10 2016-08-10 Method for providing tumour-specific t cells

Publications (1)

Publication Number Publication Date
ES2679798T3 true ES2679798T3 (es) 2018-08-31

Family

ID=56738102

Family Applications (2)

Application Number Title Priority Date Filing Date
ES16753630.9T Active ES2679798T3 (es) 2015-08-10 2016-08-10 Método para proporcionar linfocitos T específicos de tumor
ES18167345T Active ES2807026T3 (es) 2015-08-10 2016-08-10 Método para proporcionar linfocitos T específicos de tumor

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18167345T Active ES2807026T3 (es) 2015-08-10 2016-08-10 Método para proporcionar linfocitos T específicos de tumor

Country Status (6)

Country Link
US (1) US20190255162A1 (enExample)
EP (2) EP3180433B1 (enExample)
JP (1) JP6815400B2 (enExample)
DK (2) DK3372683T3 (enExample)
ES (2) ES2679798T3 (enExample)
WO (1) WO2017025564A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3908678A1 (en) * 2019-01-10 2021-11-17 Iovance Biotherapeutics, Inc. System and methods for monitoring adoptive cell therapy clonality and persistence
EP4249592A3 (en) 2021-07-15 2024-03-20 Boehringer Ingelheim International GmbH Identification of common tumor-specific t cell receptors and antigens
AU2022382915A1 (en) * 2021-11-03 2024-05-16 University Of Delaware Cell-derived microparticle delivery system and uses thereof
CN114530202A (zh) * 2021-12-20 2022-05-24 深圳泛因医学有限公司 鉴定抗原特异性tcr或bcr的方法及应用
US20250368717A1 (en) 2022-05-30 2025-12-04 Hs Diagnomics Gmbh Common tumor-specific t cell receptors
EP4649952A1 (en) 2024-05-14 2025-11-19 HS Diagnomics GmbH Kras q16h specific t cell receptors and uses thereof
WO2025238079A1 (en) 2024-05-14 2025-11-20 Hs Diagnomics Gmbh Kras q16h specific t cell receptors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128153D0 (en) * 2001-11-23 2002-01-16 Bayer Ag Profiling of the immune gene repertoire
DE102004063339A1 (de) 2004-12-23 2006-07-06 Bayer Technology Services Gmbh Sonde zum Nachweis von Nukleinsäuren
EP2653556B1 (en) * 2012-04-20 2015-09-02 Alacris Theranostics GmbH CDR sequence-specific enrichment of live immune cells
EP2746405B1 (en) 2012-12-23 2015-11-04 HS Diagnomics GmbH Methods and primer sets for high throughput PCR sequencing
US11203783B2 (en) * 2013-11-21 2021-12-21 Repertoire Genesis Incorporation T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis

Also Published As

Publication number Publication date
EP3180433B1 (en) 2018-04-18
EP3180433A1 (en) 2017-06-21
JP2018525034A (ja) 2018-09-06
DK3372683T3 (da) 2020-07-27
DK3180433T3 (en) 2018-07-30
WO2017025564A1 (en) 2017-02-16
ES2807026T3 (es) 2021-02-19
CA3030959A1 (en) 2017-02-16
JP6815400B2 (ja) 2021-01-20
EP3372683B1 (en) 2020-05-27
US20190255162A1 (en) 2019-08-22
EP3372683A1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
ES2679798T3 (es) Método para proporcionar linfocitos T específicos de tumor
US12509724B2 (en) High-throughput single-cell analysis combining proteomic and genomic information
EP4396369B1 (en) Template switch oligonucleotide (tso) for mrna 5' analysis
US20240384259A1 (en) Method and kit for labeling nucleic acid molecules
ES2992135T3 (es) Determinar secuencias de transcripción 5’
EP4097228B1 (en) Barcoded wells for spatial mapping of single cells through sequencing
US20220154288A1 (en) Combined analysis of cell-free nucleic acids and single cells for oncology diagnostics
EP3728636B1 (en) Particles associated with oligonucleotides
WO2021030627A1 (en) Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US11718872B2 (en) Method for obtaining single-cell mRNA sequence
US20210180067A1 (en) Nucleic acid aptamers
WO2023230632A2 (en) Treatment and detection of cancers having a neural-like progenitor, squamoid/basaloid/mesenchymal, or classical phenotype
KR101641920B1 (ko) EpCAM에 특이적으로 결합하는 핵산 앱타머 및 이의 용도
US20240376543A1 (en) Method for providing tumour-specific t cells
CA3030959C (en) Method for providing tumour-specific t cells
Wang et al. High-throughput and multimodal profiling of antigen-specific T cells with a droplet-based cell-cell interaction screening platform
US20250163406A1 (en) Methods for generating nucleic acid encoded protein libraries and uses thereof
WO2025072917A1 (en) Barcoding intracellular reverse transcription enables high- throughput analysis of rna sequences
Requena Aptamers as Reversible Sorting Ligands in Dual FACS and MACS: Antisense and Nuclease-Mediated Approaches
WO2023179795A1 (zh) 一种快速且简便地获得正确配对tcr的方法以及获得的tcr